UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000011897
Receipt No. R000013892
Scientific Title A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)
Date of disclosure of the study information 2013/10/01
Last modified on 2017/03/31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)
Acronym A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)
Scientific Title A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)
Scientific Title:Acronym A Phase II study of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer (OSAKA-LCSG1302)
Region
Japan

Condition
Condition Chemo-naive patients with squamous cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To investigate the efficacy and safety of q4w carboplatin plus nab-paclitaxel in chemo-naive patients with squamous cell lung cancer
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes Response rate
Key secondary outcomes Progression-free survival (PFS), PFS in cases given maintenance therapy, Overall survival (OS), Maintenance extraction rates, Frequency and grade of adverse event

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 nab-PTX 100mg/m2 (day1, 8, 15) + Carboplatin (AUC = 6, day 1) q4weeks 4cycles followed by nab-PTX 100mg/m2 (day1, 8, 15) q4weeks until disease progression
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria 1.Histologically or cytologically confirmed squamous cell lung cancer
2.Stage III/IV without any indications for radiotherapy, or recurrent disease after surgery
3.chemo-naive
4.If 12 months or more pass, the adjuvant chemotherapy is not assumed to be a previous chemotherapy
5.The picibanil used by the pleurodesis is assumed to be registrable
6.EGFR, ALK, and MET inhibitor mono-therapy does not mean previous chemotherapy
7.The patients have not been conducted radiation therapy (Except for applied palliative radiation for the primary tumor)
8.Measurable disease
9.Age 20-74
10.ECOG performance status of 0 to 1
11.Adequate organ function, evaluated within 14 days before enrollment as;
Neu >= 1,500 /mm3
Plt >= 100,000 /mm3
hemoglobin >= 9.0 g/dL
ALT (GPT) =< 100 IU/L
T. bil =< 1.5 mg/dL
Cr >= 1.5mg/dL
SpO2 >= 95% or >= 60 torr
12.Expected to live over 3 months after administration days
13.Written informed consent from the patients
Key exclusion criteria 1.Adjuvant chemotherapy of PTX
2.Active synchronous malignancy
3.Symptomatic brain metastasis
4.Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage
5.>= G2 peripheral neuropathy
6.Pneumonia or Pulmonary fibrosis detectable on chest X-rays.
7.serious complication
ischemic heart disease, cardiac arrhythmia, post-MI, hepatic cirrhosis, gastrointestinal ulcer, DM
8.History of severe drug allergy
9.Women with a possibility of pregnancy, pregnant or lactating
10.Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takashi Kijima
Organization Osaka University Hospital
Division name Dept. of Respiratory Medicine
Zip code
Address 2-15 Yamada-oka, Suita, Osaka, Japan
TEL 06-6879-3833
Email tkijima@imed3.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Takashi Kijima
Organization Osaka University Hospital
Division name Dept. of Respiratory Medicine
Zip code
Address 2-15 Yamada-oka, Suita, Osaka
TEL 06-6879-3833
Homepage URL
Email tkijima@imed3.med.osaka-u.ac.jp

Sponsor
Institute OSAKA-LCSG
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2013 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 08 Month 09 Day
Date of IRB
Anticipated trial start date
2013 Year 10 Month 01 Day
Last follow-up date
2017 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2013 Year 09 Month 27 Day
Last modified on
2017 Year 03 Month 31 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013892

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.